X
CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19). Learn More

Apalutamide (Erleada®)

Common name: Apalutamide
Brand name: Erleada®

What is Apalutamide?
 
Apalutamide has been approved for men who have non-metastatic, castrate resistant prostate cancer (nmCRPC). This means the prostate cancer:
  • has not spread to other parts of the body and
  • no longer respond to hormone therapy/androgen deprivation therapy (ADT)

How is apalutamide administered?
Apalutamide is administered orally as a tablet.

What are possible side effects of this treatment?
 
Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received apalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
 
  • Fatigue
  • Diarrhea
  • Nausea or decreased appetite
  • Weight loss
  • High blood pressure
  • Underactive thyroid gland
  • Falls
  • Broken bones
  • Joint pain
  • Rash
  • Hot flashes
  • Swelling in hands, ankles, feet







 

Is Apalutamide covered in my province or territory?
The pan-Canadian Oncology Drug Review (pCODR) recommends funding apalutamide (Erleada®) but it is not currently covered by any provincial or territorial drug program. Please talk to your doctor to learn more about apalutamide and if it is a treatment option for you.

To read pCODRs full recommendation, please click here.

For more information on pCODR, please visit www.pcodr.ca

Last reviewed: May 2019
Prostate Cancer Canada and Canadian Cancer Society








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.
More

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More


Click here for news archive